OnkoGenetiks® CGP (Kapsamlı Genomik Profilleme), DNA analizi için 513 gen ve RNA (füzyon) tespiti için 49 geni içerir; SNV, CNV, TMB, MSI ve HRD gibi anahtar parametreleri analiz ederek kanser imzalarını belirler.
Key Features
- Single-gene biomarkers: Detects single nucleotide variants (SNV), insertions and deletions, known and novel fusions, and copy number variants (CNV).
- Multi-gene biomarkers: Determines mutational predisposition through tumor mutational burden (TMB) and microsatellite instability (MSI) scoring; enables analysis of mutational signatures and assessment of potential response to immunotherapies.
- Simultaneous analysis of 49 fusion genes: Enables direct detection of 1,311 known fusion isoforms as well as novel, previously unknown fusion isoforms.
- Homologous recombination deficiency (HRD): Determines genomic instability by detecting loss of heterozygosity (LOH) at the gene and sample level in 46 key genes involved in homologous recombination repair pathways.
- Ability to work with low-input samples: 10 ng or more of tissue-derived DNA/RNA is sufficient for analysis; it offers more analysis options with less tissue than conventional tests.
- High test success: Sequencing success rates of up to 95% allow more samples to be tested without problems.
- Highly automated workflow: The automated, short processing protocol increases laboratory efficiency and reduces potential user error.
Reliability
One of the panel's key advantages is that it works with a minimal sample of just 10 ng and delivers over 99.5% sensitivity and over 97.6% specificity.
Benefits
- Targeted therapy
- Personalized treatment
- Smart drug / immunotherapy selection
- Opportunity to avoid the potential side effects of chemotherapy